NCK1 Recombinant Protein
- Known as:
- NCK1 Recombinant Protein
- Catalog number:
- XW-RP3164
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- NCK1 Recombinant Protein
Related genes to: NCK1 Recombinant Protein
- Gene:
- NCK1 NIH gene
- Name:
- NCK adaptor protein 1
- Previous symbol:
- NCK
- Synonyms:
- NCKalpha
- Chromosome:
- 3q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-11-04
- Date modifiied:
- 2016-10-05
- Gene:
- NCK1-DT NIH gene
- Name:
- NCK1 divergent transcript
- Previous symbol:
- NCK1-AS1
- Synonyms:
- SLC35G2-AS1
- Chromosome:
- 3q22.3
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2014-01-28
- Date modifiied:
- 2018-03-23
Related products to: NCK1 Recombinant Protein
Related articles to: NCK1 Recombinant Protein
- Multiple sclerosis (MS) is the most common chronic inflammatory disease affecting the brain and spinal cord, with approximately 2.8 million cases globally. This study analyzed high-throughput MS datasets to identify dysregulated RNAs and visualized novel RNA regulatory networks to uncover non-coding interactions in MS-related signaling pathways. High-throughput gene expression datasets were analyzed in R Studio to identify dysregulated mRNAs in MS patients. miRNA, lncRNA, and protein interactions were explored using miRWalk and lncRRIsearch. Pathway enrichment analysis was performed via Enrichr and KEGG, and qRT-PCR validated the gene expression results. RGS2 was found to be significantly upregulated in both microarray (logFC: 1.7667, adj.P. Value: 0.0079) and qRT-PCR analyses (logFC: 4.547, p-value < 0.0001). Similarly, the lncRNAs NCK1-DT (logFC: 2.155, p-value: 0.0132) and ASH1L-AS1 (logFC: 3.345, p-value < 0.0001) exhibited elevated expression in MS samples, suggesting a regulatory impact on RGS2 expression levels. The marked changes in the expression of RGS2, NCK1-DT, and ASH1L-AS1 in MS patients compared to normal samples position them as promising diagnostic biomarkers. Additionally, RGS2 and its associated proteins have been implicated in modulating the NF-Kappa B signaling pathway. MiR-4638-3p was identified to directly downregulate RGS2 expression, while miR-4525 influences the expression of RGS2 and ASH1L-AS1 within a competing endogenous RNA (ceRNA) network. NCK1-DT and ASH1L-AS1 are the two novel diagnostic biomarkers of MS. Mentioned lncRNAs might affect the normal regulatory mechanisms of "NF-Kappa B signaling pathway" through direct and indirect interaction with mRNA RGS2. - Source: PubMed
Publication date: 2025/09/26
Forouzanfar ParisaHashemian MohammadMahmoudian MojdehKhorsandi MelikaRezaei MohammadAzadeh Mansoureh - NCK1 Antisense RNA 1 (NCK1-AS1), alternatively named as NCK1-DT, is a long non-coding RNA (lncRNA) with important roles in the carcinogenesis. Multiple studies verified its oncogenic role in different types of cancer, including gastric cancer, non-small cell lung cancer, glioma, prostate cancer and cervical cancer. NCK1-AS1 functions as a sponge for several microRNAs, including miR-137, miR-22-3p, miR-526b-5p, miR-512-5p, miR-138-2-3p and miR-6857. In this review we present an outline of NCK1-AS1 function in malignant conditions as well as atherosclerosis. - Source: PubMed
Publication date: 2023/04/05
Taheri MohammadAskari ArianBehzad Moghadam KimiaHussen Bashdar MahmudGhafouri-Fard SoudehKiani Arda - Disease development requires the activation of complex multi-factor processes involving numerous long noncoding RNAs (lncRNAs), which describe non-protein-coding RNAs longer than 200 nucleotides. Emerging evidence indicates that lncRNAs act as essential regulators that perform pivotal roles in the pathogenesis and progression of human diseases. The mechanisms underlying lncRNA involvement in diverse diseases have been extensively explored, and lncRNAs are considered powerful biomarkers for clinical practice. The lncRNA noncatalytic region of tyrosine kinase adaptor protein 1 (NCK1) antisense 1 (NCK1-AS1), also known as NCK1 divergent transcript (NCK1-DT), is encoded on human chromosome 3q22.3 and produces a 27,274-base-long transcript. NCK1-AS1 has increasingly been characterized as a causative agent for multiple diseases. The abnormal expression and involvement of NCK1-AS1 in various biological processes have been associated with several diseases. Further exploration of the mechanisms through which NCK1-AS1 contributes to disease development and progression will provide a foundation for potential clinical applications of NCK1-AS1 in the diagnosis and treatment of various diseases. This review summarizes the current understanding of the various functions and mechanisms through which NCK1-AS1 contributes to various diseases and the clinical application prospects for NCK1-AS1. - Source: PubMed
Publication date: 2022/09/21
Wang YingfanPan JieSun Zongzong - The progression, metastasis, and prognosis of cervical cancer (CC) is influenced by the tumor immune microenvironment. Studies proved that long non-coding RNAs (lncRNAs) to engage in cervical cancer development, especially immune-related lncRNAs, have emerged crucial in the tumor immune process. This study was set out to identify an immune-related lncRNA signature. In total, 13,838 lncRNA expression profiles and 328 immune genes were acquired from the clnical data of 306 CC tissues and 3 non-CC tissues. From the 433 identified immune-related lncRNAs, 4 candidate immune-related lncRNAs (SOX21-AS1, AC005332.4, NCK1-DT, LINC01871) were considered independent indicators of cervical cancer prognosis through the univariate and multivariate Cox regression analysis, and they were used to construct a prognostic and survival lncRNA signature model followed by the bootstrap method for further verification. Kaplan-Meier curves illustrated that cervical cancer patients could be divided into high-risk and low-risk groups with significant differences (P = 2.052e - 05), and the discrepancy of immune profiles between these two risk groups was illustrated by principal components analysis. Taken together, the novel survival predictive model created by the four immune-related lncRNAs showed promising clinical prediction value in cervical cancer. - Source: PubMed
Publication date: 2021/11/30
Xu MinZhang RunjieQiu Jin - A comprehensive study focusing on immune-related long non-coding RNAs (lncRNAs) in cervical cancer (CC) was performed. Through the integration of TCGA data, a total of 266 immune-related lncRNAs were obtained. We defined all samples as an entire set, and randomly divided them into train set and test set at a ratio of 1:1. Univariate, LASSO and multivariate Cox regression analyses were carried out based on train set for key lncRNAs (UBL7-AS1, AC083809.1, LIPE-AS1, PCED1B-AS1, ELFN1-AS1 and NCK1-DT) to construct a prognostic model, while the others were used for validation. The overall survival (OS) suggested that we may have longer survival expectations for patients classified into the low-risk group. The values of risk score in univariate analysis and multivariate analysis were all less than 0.05, indicating the ability of risk score to independently assess the prognosis of patients. For clinical application, a nomogram with a high degree of agreement between the predicted curve and the actual curve was constructed. Subsequently, immune status and chemotherapy response were investigated in two prognostic subtypes. The associations between risk score and immune cell were estimated, in which CD8+ T cells showed the highest positive correlation and activated mast cell showed the highest negative correlation. In addition, checkpoint proteins (CTLA4, LAG3, PD-1, and TIGIT) showing negative correlation with risk score were found to be upregulated in low-risk group. A total of 3 chemotherapy drugs including paclitaxel, vinorelbine and methotrexate were considered effective in patients of high-risk group. Using 6 key immune-related lncRNAs, we identified two prognostic subtypes and provided new insights for CC immunotherapy. - Source: PubMed
Publication date: 2021/10/15
Liu JinhuiLiu YinghuiGao FengZhang JianguoPan JiadongLiu YifeiZhu Hongjun